VEGFR-2 car immune cells to treat cancers
AssigneeHelix BioPharma Corporation
InventorsHeman Lap Man Chao, Wah Yau Wong, Baomin Tian, Marni Diane Uger
Life of this patent
Estimating the term…
Abstract
Compositions and methods for treating cancer in humans are provided using CARs. The invention includes engineered CARs (chimeric receptor antigens) and genetically modified immune cells that express such a CAR with a high affinity for VEGFR. More specifically, the cells are CAR-T cells recognizing VEGFR-2 on solid tumors, uses thereof, compositions thereof and methods of making. The invention includes therapeutic methods to treat VEGFR-2 dependent cancers targeting tumor angiogenesis. A chimeric antigen receptor (CAR) that binds to VEGFR-2, an epitope or fragment thereof, or a variant thereof.
Claims25
A chimeric antigen receptor (CAR) that binds to VEGFR-2, an epitope or fragment thereof, or a variant thereof, wherein said CAR comprises a single domain antibody or a fragment thereof for binding to VEGFR-2, and wherein said CAR comprises the sequence of SEQ ID NO:78 or a sequence at least 90% identical thereto.
Dependencies are inferred from the claim text.